<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Matrix metalloproteinases (MMPs) have been implicated to play an important role in the destruction of the extracellular matrix in diseases of the central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated whether the expression of one of these proteases, MMP-9 in blood, is related to the size of human brain <z:mpath ids='MPATH_124'>infarcts</z:mpath> assessed with magnetic resonance imaging </plain></SENT>
<SENT sid="2" pm="."><plain>Consecutively, twenty-one <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients were included prospectively into our study </plain></SENT>
<SENT sid="3" pm="."><plain>In blood samples drawn within 24 h after <z:hpo ids='HP_0003674'>onset</z:hpo>, MMP-9 RNA-expression and proteolytic-activity were analyzed by quantitative polymerase chain reaction and gelatin zymography, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The ischemic lesion volumes in time to peak perfusion maps and diffusion weighted imaging were measured morphometrically </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi>-expression levels of MMP-9 in peripheral blood mononuclear cells (PBMCs) correlated with the brain <z:mpath ids='MPATH_124'>infarct</z:mpath> lesion (<z:chebi fb="1" ids="18284">TTP</z:chebi>-delay 4 s, r = -0.61, p = 0.007; <z:chebi fb="1" ids="18284">TTP</z:chebi>-delay 6 s: r = -0.58, p = 0.012; DWI r = -0.47; p = 0.047) </plain></SENT>
<SENT sid="6" pm="."><plain>Our preliminary results demonstrate that MMP-9 RNA is upregulated in PBMCs in proportion to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that MMP-9 might contribute to the manifestation of ischemic brain damage </plain></SENT>
<SENT sid="8" pm="."><plain>Since MMP-9 is upregulated in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> inhibition of MMP-9 may represent a complementary treatment target in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy </plain></SENT>
</text></document>